| Properties | Memantine | Hymenialdisine | Tideglusib | Kenpaullone | Dihydrospiro [dibenzo[a,d] [7] annulene -5,4’-imidazol] | Harmine | Harmol | 1-Methyl-4-Phenylpyridinium |
| Blood-Brain Barrier | BBB+ | BBB+ | BBB+ | BBB+ | BBB+ | BBB+ | BBB+ | BBB+ |
| Human Intestinal Absorption | HIA+ | HIA+ | HIA+ | HIA+ | HIA+ | HIA+ | HIA+ | HIA+ |
| Caco-2 Permeability | Caco2+ | Caco2− | Caco2− | Caco2− | Caco2− | Caco2− | Caco2− | Caco2+ |
| P-glycoprotein Substrate | Non-substrate | Substrate | Non-substrate | Non-substrate | Substrate | Non-substrate | Substrate | Non-substrate |
| P-glycoprotein Inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor |
| Renal Organic Cation Transporter | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor |
| Subcellular localization | Lysosome | Mitochondria | Mitochondria | Mitochondria | Lysosome | Mitochondria | Mitochondria | Mitochondria |
| CYP450 2C9 Substrate | Non-substrate | Non-substrate | Non-substrate | Non-substrate | Non-substrate | Non-substrate | Non-substrate | Non-substrate |
| CYP450 2D6 Substrate | Non-substrate | Non-substrate | Non-substrate | Non-substrate | Non-substrate | Non-substrate | Non-substrate | Non-substrate |
| CYP450 3A4 Substrate | Non-substrate | Substrate | Non-substrate | Substrate | Substrate | Non-substrate | Non-substrate | Non-substrate |
| CYP450 1A2 Inhibitor | Non-inhibitor | Inhibitor | Non-inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Non-inhibitor |
| CYP450 2C9 Inhibitor | Non-inhibitor | Non-inhibitor | Inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor |
| CYP450 2D6 Inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Inhibitor | Non-inhibitor | Inhibitor | Inhibitor | Non-inhibitor |
| CYP450 2C19 Inhibitor | Non-inhibitor | Non-inhibitor | Inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor |
| CYP450 3A4 Inhibitor | Non-inhibitor | Non-inhibitor | Non-inhibitor | Inhibitor | Non-inhibitor | Inhibitor | Non-inhibitor | Non-inhibitor |
| CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | High CYP Inhibitory Promiscuity | High CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | High CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | High CYP Inhibitory Promiscuity |
| AMES Toxicity | Non-AMES toxic | Non-AMES toxic | Non-AMES toxic | Non-AMES toxic | Non-AMES toxic | AMES-toxic | AMES-toxic | Non-AMES toxic |
| Carcinogens | Non-carcinogens | Non-carcinogens | Non-carcinogens | Non-carcinogens | Non-carcinogens | Non-carcinogens | Non-carcinogens | Non-carcinogens |
| Biodegradation | Not ready biodegradable | Not ready biodegradable | Not ready biodegradable | Not ready biodegradable | Not ready biodegradable | Not ready biodegradable | Not ready biodegradable | Not ready biodegradable |
| Acute Oral Toxicity | III | III | III | III | III | III | III | III |